NCT02396628 - Ruxolitinib In GvHD | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 29, 2017

Primary Completion Date

November 15, 2019

Study Completion Date

November 15, 2019

Conditions

Graft vs Host Disease

Interventions

DRUG

Experimental intervention

Treatment with Ruxolitinib at a dose of 10 mg BID orally addition to BAT according DGHO-Onkopedia guidelines

DRUG

Standard treatment

Treatment according to DGHO-Onkopedia guidelines for treatment of acute GvHD (as of March 2018). Optional cross over from BAT to Ruxolitinib and BAT in case of lack of response from day 28.

Trial Locations (11)

13353

Charité - Universitätsmedizin Berlin, Berlin

20246

Universitätsklinikum Hamburg Eppendorf, Hamburg

35043

Universitätsklinikum Marburg, Marburg

50937

Universitätsklinikum Köln, Cologne

53105

Universitätsklinikum Bonn, Bonn

66421

Universitätsklinikum des Saarlandes, Homburg

69120

Universitätsklinikum Heidelberg, Heidelberg

79106

University Medical Center, Freiburg im Breisgau

81675

Universitätsklinikum München TU rechts der Isar, München

97080

Universitätsklinikum Würzburg, Würzburg

01307

Universitätsklinikum Dresden, Dresden